Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 3
1975 2
1977 1
1979 1
1980 2
1981 1
1983 2
1984 1
1986 1
1987 3
1988 1
1989 1
1990 2
1991 2
1992 3
1993 3
1994 1
1995 1
1996 1
1997 1
1998 2
1999 1
2000 1
2001 1
2002 2
2003 2
2005 2
2006 5
2007 3
2008 2
2009 2
2010 4
2011 2
2012 5
2013 4
2014 3
2015 2
2016 5
2017 3
2018 5
2019 5
2020 4
2021 4
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia.
Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML, Clifton-Bligh R, Collins M, Florenzano P, Houillier P, Imanishi Y, Imel EA, Khan AA, Zillikens MC, Fukumoto S. Jan de Beur SM, et al. J Intern Med. 2023 Mar;293(3):309-328. doi: 10.1111/joim.13593. Epub 2022 Dec 13. J Intern Med. 2023. PMID: 36511653 Free PMC article. Review.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). ...Patients with the clinical/biochemical suspicion of TIO should be referred to a specialist for diagnosis confirmation …
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth …
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D. Haffner D, et al. Pediatr Nephrol. 2022 Oct;37(10):2289-2302. doi: 10.1007/s00467-022-05505-5. Epub 2022 Mar 29. Pediatr Nephrol. 2022. PMID: 35352187 Free PMC article.
Fibroblast-growth factor 23 (FGF23)-associated hypophosphatemic rickets was historically treated with frequent doses of oral phosphate salts in combination with active vitamin D, whereas tumor-induced osteomalacia (TIO) should primarily undergo tumor resection, if p …
Fibroblast-growth factor 23 (FGF23)-associated hypophosphatemic rickets was historically treated with frequent doses of oral phosphate salts …
Management of acute kidney injury in symptomatic multiple myeloma.
Bridoux F, Leung N, Belmouaz M, Royal V, Ronco P, Nasr SH, Fermand JP; International Kidney and Monoclonal Gammopathy Research Group. Bridoux F, et al. Kidney Int. 2021 Mar;99(3):570-580. doi: 10.1016/j.kint.2020.11.010. Epub 2021 Jan 10. Kidney Int. 2021. PMID: 33440212 Review.
Kidney biopsy may be helpful in guiding management and assessing renal prognosis that appears to depend on the extent of cast formation and interstitial fibrosis/tubular atrophy. Because of continuous improvement in life expectancy of patients with multiple myeloma, …
Kidney biopsy may be helpful in guiding management and assessing renal prognosis that appears to depend on the extent of cast formati …
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Gill AJ. Trpkov K, et al. Mod Pathol. 2021 Jul;34(7):1392-1424. doi: 10.1038/s41379-021-00779-w. Epub 2021 Mar 4. Mod Pathol. 2021. PMID: 33664427 Free article.
Papillary RCC subtyping is no longer recommended, as WHO/ISUP grade and tumor architecture better predict outcome. New papillary RCC variants/patterns include biphasic, solid, Warthin-like, and papillary renal neoplasm with reverse polarity. For tumors with ' …
Papillary RCC subtyping is no longer recommended, as WHO/ISUP grade and tumor architecture better predict outcome. New papillary RCC …
Non-renal effects and the risk assessment of environmental cadmium exposure.
Åkesson A, Barregard L, Bergdahl IA, Nordberg GF, Nordberg M, Skerfving S. Åkesson A, et al. Environ Health Perspect. 2014 May;122(5):431-8. doi: 10.1289/ehp.1307110. Epub 2014 Feb 25. Environ Health Perspect. 2014. PMID: 24569905 Free PMC article. Review.
Under the currently prevailing health risk assessment, the relationship between urinary Cd (U-Cd) concentrations and tubular proteinuria is used. However, doubts have recently been raised regarding the justification of basing the risk assessment on this relationship at ver …
Under the currently prevailing health risk assessment, the relationship between urinary Cd (U-Cd) concentrations and tubular proteinu …
Nephrogenic Adenoma: Clinical Features, Management, and Diagnostic Pitfalls.
Gordetsky J, Gennaro KH, Selph JP, Rais-Bahrami S. Gordetsky J, et al. Urology. 2016 Sep;95:29-33. doi: 10.1016/j.urology.2016.04.032. Epub 2016 Apr 29. Urology. 2016. PMID: 27138263 Review.
OBJECTIVE: To review the diagnosis and management of nephrogenic adenoma (NA), an uncommon benign lesion found in the urinary tract. This lesion arises from a proliferation of implanted renal tubular cells. Although more common in adults, it can occur in all ages. . …
OBJECTIVE: To review the diagnosis and management of nephrogenic adenoma (NA), an uncommon benign lesion found in the urinary tract. This le …
Management of multiple myeloma bone disease: impact of treatment on renal function.
Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kanellias N, et al. Expert Rev Hematol. 2018 Nov;11(11):881-888. doi: 10.1080/17474086.2018.1531702. Epub 2018 Oct 20. Expert Rev Hematol. 2018. PMID: 30285492 Review.
Areas covered: The aim of this review is to present the possible adverse profile of bisphosphonates (BPs) on renal function, the underlying mechanisms by which BPs may affect renal function and the novel therapeutic approaches on myeloma bone disease manageme …
Areas covered: The aim of this review is to present the possible adverse profile of bisphosphonates (BPs) on renal function, the unde …
Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Skinner R. Skinner R. Pediatr Nephrol. 2018 Feb;33(2):215-225. doi: 10.1007/s00467-017-3662-z. Epub 2017 Apr 22. Pediatr Nephrol. 2018. PMID: 28434047 Free PMC article. Review.
Up to 20% of children display evidence of chronic glomerular damage after unilateral nephrectomy for a renal tumour. Overall, childhood cancer survivors have a ninefold higher risk of developing renal failure compared with their siblings. Such chronic nephrot …
Up to 20% of children display evidence of chronic glomerular damage after unilateral nephrectomy for a renal tumour. Overall, …
Renal complications from bisphosphonate treatment.
Hirschberg R. Hirschberg R. Curr Opin Support Palliat Care. 2012 Sep;6(3):342-7. doi: 10.1097/SPC.0b013e328356062e. Curr Opin Support Palliat Care. 2012. PMID: 22710581 Review.
PURPOSE OF REVIEW: More than 10 years ago evidence emerged that bisphosphonate therapy especially in malignant bone diseases is associated with renal complications. ...Other types of renal injury include transient but self-limited rises in creatinine, and, ve …
PURPOSE OF REVIEW: More than 10 years ago evidence emerged that bisphosphonate therapy especially in malignant bone diseases is assoc …
Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies.
Troxell ML, Higgins JP, Kambham N. Troxell ML, et al. Adv Anat Pathol. 2016 Sep;23(5):310-29. doi: 10.1097/PAP.0000000000000122. Adv Anat Pathol. 2016. PMID: 27403615 Review.
Cisplatin, pemetrexed, and ifosfamide are well-known causes of acute tubular injury/necrosis. Acute interstitial nephritis seems underrecognized in this clinical setting. ...Cancer patients are historically underbiopsied, but biopsy can reveal type, acuity, and chronicity …
Cisplatin, pemetrexed, and ifosfamide are well-known causes of acute tubular injury/necrosis. Acute interstitial nephritis seems unde …
103 results